Clinical review of Lallemand Probiokid shows immune benefits

The product, aimed at infant and children applications, is offered as a ready-to-market probiotic formulation in different formats such as bulk powder, sachets, orodispersible sticks and drops

A review of clinical studies on Lallemand Health Solutions’ Probiokid formulation has been published in Nutrients, summarising the clinical studies in infants and children, including the safety studies, to evaluate the probiotic’s efficacy.

Probiokid combines Lactobacillus helveticus Rosell-52, Bifidobacterium infantis Rosell-33, Bifidobacterium bifidum Rosell-71 and fructooligosaccharides. With a total of 28 clinical studies, Probiokid is one of the company’s most documented probiotic formulations, it says, and can be marketed under different product categories depending on applicable regulatory provisions.

The review includes twelve studies showing the probiotic significantly increases the efficacy of standard diarrhoea treatment regardless of etiology by 69%. It also discusses eight studies which show the probiotic enhanced immune defences, assessed by levels of immune competence and mucosal immunity markers, in addition to reduced incidence of common infections. Three further studies show the probiotic improved iron-deficiency treatment efficacy, significantly reducing treatment side effects by 47%.

Other studies support further investigation into this probiotic for oral candidiasis, eczema, feeding intolerance in premature babies, or hyperbilirubinemia in newborns, Lallemand says.

“Probiokid is a real superhero for infant and child immunity, proven efficient to support immune system maturation and gut microflora. This comprehensive review recaps why it has been the most popular pediatric probiotic product in the world in the last decade” said Morgane Maillard, Product Manager, at Lallemand Health Solutions.

Probiokid single strains have been authorised for use in infant food in China. Both combination and single strains have been notified as generally recognised as safe (GRAS) by the FDA for non-exempt infant formula. In Canada, the probiotic combination has been granted health claims that it helps to reinforce the body’s natural defenses and participates to the microflora balance in children, and that it could promote a favourable gut flora and is a source of probiotics from three months old babies, up to older children.

The product is offered as a ready-to-market probiotic formulation in different formats such as bulk powder, sachets, orodispersible sticks and drops.

Featured Companies

Lallemand Health Solutions (more information, website)